Patents by Inventor Kenneth Blum
Kenneth Blum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220177952Abstract: Methods for assessing severity index for genetic risks for post-traumatic stress disorders and behavioral management thereof. In some embodiments, the methods provide a risk analysis score (termed a “genetic risk post-traumatic stress disorders score”). The method for behavioral management of those depending upon the individual's genetic risk post-traumatic stress disorders score is termed a precision behavioral management (or “PBM”) protocol.Type: ApplicationFiled: March 18, 2020Publication date: June 9, 2022Applicant: Geneus Health, LLCInventor: Kenneth Blum
-
Publication number: 20210251929Abstract: Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis are disclosed. These compounds synergistically combine two or more of (a) DPA, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostasis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In some embodiments, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DPA, NAC, and kyotorphin are not soluble in water.Type: ApplicationFiled: January 19, 2021Publication date: August 19, 2021Applicant: Synaptamine, Inc.Inventor: Kenneth Blum
-
Patent number: 10894024Abstract: Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis. These compounds synergistically combine two or more of (a) DP A, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostatis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In embodiments of the present invention, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DP A, NAC, and kyotorphin are not soluble in water.Type: GrantFiled: December 7, 2015Date of Patent: January 19, 2021Assignee: SYNAPTAMINE, INC.Inventor: Kenneth Blum
-
Publication number: 20190112644Abstract: Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.Type: ApplicationFiled: December 19, 2018Publication date: April 18, 2019Applicant: SYNAPTAMINE, INC.Inventor: Kenneth Blum
-
Patent number: 10072289Abstract: Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.Type: GrantFiled: July 10, 2015Date of Patent: September 11, 2018Assignee: IGENE LLCInventor: Kenneth Blum
-
Publication number: 20170360734Abstract: Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis. These compounds synergistically combine two or more of (a) DP A, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostatis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In embodiments of the present invention, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DP A, NAC, and kyotorphin are not soluble in water.Type: ApplicationFiled: December 7, 2015Publication date: December 21, 2017Applicant: SYNAPTAMINE, INC.Inventor: Kenneth Blum
-
Publication number: 20160032369Abstract: Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.Type: ApplicationFiled: September 24, 2015Publication date: February 4, 2016Applicant: SYNAPTAMINE, INC.Inventor: Kenneth Blum
-
Publication number: 20160032391Abstract: Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.Type: ApplicationFiled: September 24, 2015Publication date: February 4, 2016Applicant: SYNAPTAMINE, INC.Inventor: Kenneth Blum
-
Publication number: 20160012180Abstract: Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.Type: ApplicationFiled: July 10, 2015Publication date: January 14, 2016Applicant: SYNAPTAMINE, INC.Inventor: Kenneth Blum
-
Publication number: 20150072881Abstract: The present invention relates to methods to objectively assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors by obtaining expression profiles (e.g., mRNA expression and/or protein expression profiles) for one or more genes at two or more different time points, for example, before and after treating a subject known to have or suspected of having an RDS affliction. Analysis, for example, of mRNA and/or protein expression levels and/or patterns can be conducted before admission to a treatment facility, followed by testing at one or more various designated times during and after a subject's treatment. Such methods may also be combined with other tests, and can be used in diagnosis and treatment of RDS and RDS behaviors, including drug and/or alcohol abuse and addiction, overeating, gambling, sexual addiction, etc.Type: ApplicationFiled: April 7, 2014Publication date: March 12, 2015Inventor: Kenneth BLUM
-
Publication number: 20130195827Abstract: This invention concerns Reward Deficiency Syndrome (RDS) and obesity, and the role of catecholaminergic pathways in aberrant substance-seeking behavior, in particular cravings for carbohydrates. Also described are new nutrigenomic formulas having unique combinations of ingredients having a generalized anti-craving effect are, which can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention, as well genetic testing for certain polymorphisms correlated with RDS behaviors.Type: ApplicationFiled: September 27, 2012Publication date: August 1, 2013Inventors: Kenneth Blum, B. William Downs, Roger L. Waite, William J. Heaney
-
Publication number: 20120142543Abstract: The present invention relates to methods to objectively assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors by obtaining expression profiles (e.g., mRNA expression and/or protein expression profiles) for one or more genes at two or more different time points, for example, before and after treating a subject known to have or suspected of having an RDS affliction. Analysis, for example, of mRNA and/or protein expression levels and/or patterns can be conducted before admission to a treatment facility, followed by testing at one or more various designated times during and after a subject's treatment. Such methods may also be combined with other tests, and can be used in diagnosis and treatment of RDS and RDS behaviors, including drug and/or alcohol abuse and addiction, overeating, gambling, sexual addiction, etc.Type: ApplicationFiled: November 29, 2011Publication date: June 7, 2012Inventor: Kenneth Blum
-
Publication number: 20120071409Abstract: A formulation delivery system is disclosed. When configured as a pro-liposome oral tablet, the tablet comprises a blend of at least one Iiposome forming ingredient, at least one active ingredient and at least one co-disintegrant. After ingestion at least a portion of the tablet disintegrates in a portion of an alimentary system to provide one or more in situ Iiposome encapsulated active ingredients. A method of producing the pro-liposome oral tablet and a method of therapeutically dosing with the pro-liposome oral tablet are further disclosed. The formulation delivery system may be configured as any one of a pro-liposome oral tablet, sublingual tablet, caplet, capsule and aerosol.Type: ApplicationFiled: March 8, 2011Publication date: March 22, 2012Inventors: Jacob C. Hack, Richard D. Tobias, Kenneth Blum, B. William Downs, Roger L. Waite, William J. Heaney, John J. Giordano
-
Publication number: 20120053070Abstract: Methods and kits for performing genetic analyses of biological samples to assess predisposition for and/or to stratify risk Reward Deficiency Syndrome (RDS) behavior, including various addictive and/or compulsive behaviors, are described. The methods and kits of the invention use different nucleic acid probes to determine if a human subject's genome contains one or more alleles for one or more genes implicated in RDS.Type: ApplicationFiled: April 22, 2011Publication date: March 1, 2012Inventors: Kenneth Blum, William B. Downs, Roger L. Waite, William J. Heaney
-
Publication number: 20120022610Abstract: A new class of therapeutic neuro-electro-adaptive devices for delivering cranial electrotherapy (NEAT) to patients for the treatment of various diseases and disorders, including those involving Reward Deficiency Syndrome (RDS), are described, as are various methods for using such devices, for example, to treat RDS behaviors.Type: ApplicationFiled: April 22, 2011Publication date: January 26, 2012Inventors: Kenneth Blum, Roger L. Waite, Bernard William Downs, William J. Heaney
-
Publication number: 20110189161Abstract: The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions.Type: ApplicationFiled: June 22, 2009Publication date: August 4, 2011Inventors: Kenneth Blum, Roger L. Waite, B. William Downs, William J. Heaney
-
Patent number: 7991466Abstract: Methods and apparatus to restore central and peripheral disorders/dysfunction caused by edema, ischemia, and nitric oxide (NO) deficiency and to improve or facilitate muscle performance (e.g. endurance and recovery) by utilizing a device which stimulates cell initiated NO activation, promotes interstitial protein clearance, and induces angiogenesis. By use of these methods and apparatus, it is possible to treat a number of disorders/diseases caused by a deficiency of nitric oxide, a lack of proper circulation and vascularity, a build up of proteins and increased tissue water content due to injury; and to improve or facilitate muscle performance (e.g., muscle endurance and muscle recovery.Type: GrantFiled: October 15, 2008Date of Patent: August 2, 2011Assignee: Electronic Waveform Lab, Inc.Inventors: Kenneth Blum, William J. Heaney, Roger L. Waite
-
Publication number: 20090240304Abstract: Methods and apparatus to restore central and peripheral disorders/dysfunction caused by edema, ischemia, and nitric oxide (NO) deficiency and to improve or facilitate muscle performance (e.g. endurance and recovery) by utilizing a device which stimulates cell initiated NO activation, promotes interstitial protein clearance, and induces angiogenesis. By use of these methods and apparatus, it is possible to treat a number of disorders/diseases caused by a deficiency of nitric oxide, a lack of proper circulation and vascularity, a build up of proteins and increased tissue water content due to injury; and to improve or facilitate muscle performance (e.g., muscle endurance and muscle recovery.Type: ApplicationFiled: October 15, 2008Publication date: September 24, 2009Inventors: Kenneth Blum, William J. Heaney, Roger L. Waite
-
Publication number: 20070175666Abstract: An auger bit is provided for a foundation pile system including a drilling rig adapted for mounting and rotating a grout pipe connected to the auger bit to form an auger. The auger bit includes a stem with lower and upper sections, which taper towards a transition whereat the stem has a maximum diameter. A pile foundation forming method includes the steps of providing a drilling rig, forming an auger with a grout pipe coupled to an auger bit, rotating the auger with the rig, forming a borehole with laterally displaced soil, pumping pressurized grout through the auger and into the borehole, placing a reinforcing cage in the wet grout and curing same.Type: ApplicationFiled: April 3, 2007Publication date: August 2, 2007Applicant: Berkel & Company Contractor, Inc.Inventor: Kenneth Blum
-
Publication number: 20060079495Abstract: The present invention relates to a kit and an intravenously administrable preparation, both with a signal transmitter precursor, an enhancer of precursor uptake, and an inhibitor of neurotransmitter reuptake or signal transmitter catabolism. The kit also contains an appropriate swab for obtaining oral cells suitable for allelic analysis. The intravenous formulation contains similar materials and, in some cases, ethanol. Either the kit composition or the intravenous formulation may be used as guided by a subjects allelic analysis. Collections of particular alleles, especially those relating to neural system are comprehensible in terms of likelihood of success in the administration of an intraveinous formulation or ingestion of components of the subject kit.Type: ApplicationFiled: October 14, 2005Publication date: April 13, 2006Inventor: Kenneth Blum